This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
5 Large Drug Stocks to Keep An Eye On in the New Year
by Kinjel Shah
R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio.
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) concluded the recent trading session at $177.70, signifying a +0.85% move from its prior day's close.
AbbVie (ABBV) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
AbbVie (ABBV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Anavex Life Sciences (AVXL) This Year?
by Zacks Equity Research
Here is how Anavex Life Sciences (AVXL) and AbbVie (ABBV) have performed compared to their sector so far this year.
Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Should Invesco Large Cap Value ETF (PWV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PWV
AbbVie (ABBV) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $180, marking a +0.9% move from the previous day.
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals
by Kinjel Shah
PFE issues its financial guidance for 2025. MRK and ABBV announce M&A deals. SNY/TEVA's IBD drug succeeds in a phase IIb study.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
by Zacks Equity Research
Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage study for Ulcerative colitis and Crohn's disease indications.
Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn into More Strength?
by Zacks Equity Research
Sanofi (SNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DHS
4 Big Drug Stocks That May Continue to Outperform in 2025
by Kinjel Shah
Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum in 2025.
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the most recent trading session, AbbVie (ABBV) closed at $171.63, indicating a -1% shift from the previous trading day.
ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?
by Kinjel Shah
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
by Zacks Equity Research
AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.
EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease
by Zacks Equity Research
The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or without prior biologic failure.
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DHS
AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal
by Zacks Equity Research
Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's disease.
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group
by Zacks Equity Research
Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group are included in this Analyst Blog.
Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc. (ABBV) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks, Air T, Inc. (AIRT) and Fossil Group, Inc. (FOSL).
Pfizer Stock Falls 8% in a Month: Should You Buy the Dip?
by Kinjel Shah
Investors with a long-term horizon may consider buying PFE stock at its present attractive valuation.